RxDoctor Payments Data

Raimundo Acosta, MD

Cardiovascular Disease · Miami Beach, FLNPI 1245280650

Payments from drug & device makers

$18,627in general payments, 2019–2025

Across 212 payments — averaging $87.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$6K
  • Akcea Therapeutics, Inc.$6K
  • AstraZeneca$2K
  • Novartis$2K
  • Pfizer$342
  • Astellas Pharma US Inc$298
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,67094%
  • Education$2506%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,627 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$438,030
Medicare patients
659
Services billed
4,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban326$377,228
EntrestoSacubitril/Valsartan174$242,671
Repatha SureclickEvolocumab161$119,534
LinzessLinaclotide64$77,572
VascepaIcosapent Ethyl104$61,925
JardianceEmpagliflozin38$57,135
XareltoRivaroxaban38$49,032
OzempicSemaglutide33$32,068
Repatha SyringeEvolocumab36$30,076
JanuviaSitagliptin Phosphate23$26,262
MounjaroTirzepatide25$25,268
LivaloPitavastatin Calcium27$15,802
Praluent PenAlirocumab24$14,202
CreonLipase/Protease/Amylase17$12,922
Nebivolol Hcl128$10,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$342$377,228326 claims
NovartisEntresto$1,515$242,671174 claims
AbbVieLinzess, Creon, Synthroid$52$93,631106 claims
Boehringer IngelheimJardiance$76$57,13538 claims
Johnson & JohnsonXarelto$207$49,03238 claims
Novo NordiskOzempic$15$32,06833 claims
AmgenCorlanor$17$7,39415 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$22$5,75515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →